Critical Limb Ischemia Treatment Market Size and Share

Critical Limb Ischemia Treatment Market (2026 - 2031)

Critical Limb Ischemia Treatment Market Analysis by Mordor Intelligence

The Critical Limb Ischemia Treatment Market size was valued at USD 5.19 billion in 2025 and is estimated to grow from USD 5.47 billion in 2026 to reach USD 7.03 billion by 2031, at a CAGR of 5.15% during the forecast period (2026-2031).

Device-based revascularization remains the cornerstone of therapy; however, its 62.81% revenue share in 2025 disguises a decisive pivot toward regenerative and cell-based options, which are expanding at more than double the overall pace. Hospitals, ambulatory surgical centers, and multispecialty vascular clinics are increasing access to these newer modalities as payers reward therapies that reduce re-intervention rates and prevent amputation. At the same time, emerging markets are unlocking latent demand through local approvals of cost-efficient drug-eluting balloons, offsetting slower growth in Europe where paclitaxel safety reviews have dampened enthusiasm for specific devices. Competitive intensity is intensifying as established device vendors defend their share against biologics start-ups, AI imaging specialists, and low-cost regional manufacturers.

Key Report Takeaways

  • By treatment type, devices held 62.81% of the critical limb ischemia treatment market share in 2025, while regenerative and cell-based therapies are projected to advance at a 10.06% CAGR through 2031. 
  • By end-user, hospitals captured 46.03% share of the critical limb ischemia treatment market size in 2025, and ambulatory surgical centers are expanding at a 10.72% CAGR through 2031. 
  • By geography, North America commanded 44.32% revenue share in 2025; Asia-Pacific is forecast to post the fastest 11.53% CAGR to 2031. 

Note: Market size and forecast figures in this report are generated using Mordor Intelligence’s proprietary estimation framework, updated with the latest available data and insights as of January 2026.

Critical Limb Ischemia Treatment Market Segment Analysis

By Treatment Type:

Regenerative Therapies Outpace Devices Despite Smaller Base

Devices accounted for 62.81% of 2025 revenue, anchored by drug-eluting stents, plain balloons, and atherectomy systems. Embolic protection devices accounted for just 3% of device revenue, as they are primarily reserved for high-risk distal work. Peripheral dilatation systems, such as Cardiovascular Systems’ Diamondback 360, grew 14% year-over-year, displacing plain angioplasty in calcified lesions. The growth of vascular and drug-eluting stents softened to a 3.2% CAGR amid headwinds from paclitaxel. Regenerative and cell-based therapies held an 8% share in 2025, but their 10.06% CAGR positions them to erode repeat device revenue, as successful biologic repair lowers re-intervention rates. 

Critical Limb Ischemia Treatment Market: Market Share by Treatment Type
Critical Limb Ischemia Treatment Market: Market Share by Treatment Type

By End-User:

Ambulatory Surgical Centers Capture Complex Procedures

Hospitals still accounted for 46.03% of the revenue in 2025; however, payer steering and bundled payments are shifting suitable cases to ambulatory environments that deliver similar outcomes at a lower cost. Ambulatory surgical centers executed 28% of U.S. CLI interventions in 2025 and are growing at a 10.72% CAGR, lifted by CMS coverage of below-the-knee angioplasty since 2024. Office-based labs, a subset of ASCs, accounted for 35% of Boston Scientific’s Ranger balloon sales in 2025, up from 18% in 2023, confirming a shift in channel economics. The specialty vascular and wound-care clinics segment is growing at a rapid pace, as integrated care models demonstrate a 40% reduction in major amputations.

Critical Limb Ischemia Treatment Market: Market Share by End-User
Critical Limb Ischemia Treatment Market: Market Share by End-User

Geography Analysis

North America Critical Limb Ischemia Treatment Market

North America dominated with a 44.32% share in 2025, due to U.S. Medicare’s generous reimbursement, which underpins device usage. However, scrutiny of paclitaxel and a mature installed base temper the acceleration. Canada reimburses CLI at CAD 8,500 (USD 6,300), which is 25% below U.S. rates, thereby restraining premium adoption. Mexico expanded its vascular capacity by 18% between 2023 and 2025; however, specialist scarcity continues to keep guideline adherence below 40%. U.S. limb-preservation protocols delivered via telehealth are opening adjacent Latin markets to American devices, further consolidating supplier advantage.

Germany and United Kingdom Critical Limb Ischemia Treatment Market

Germany halted broad paclitaxel reimbursement in 2024, resulting in a one-third reduction in national sales. Conversely, the United Kingdom issued positive guidance for LimFlow’s deep vein arterialization system in 2026, creating a GBP 45 million (USD 57 million) opportunity. 

APAC Critical Limb Ischemia Treatment Market

Asia-Pacific is the growth driver with an 11.53% CAGR. China’s approval of 14 home-grown drug-eluting devices between 2024 and 2025 reduced local prices by 60%, unlocking rural demand and expanding the critical limb ischemia treatment market size in the region. Japan grows 5.2% as reimbursement for cell therapies rose 18% in 2025. Australia’s TGA green-lit Cynata’s Cymerus therapy for compassionate use in 2025, reinforcing its role as a regenerative test bed.

MEA Critical Limb Ischemia Treatment Market

Saudi Arabia has earmarked SAR 12 billion (approximately USD 3.2 billion) for 50 limb-preservation clinics by 2028. The UAE’s 2024 fast-track pathway shrank device approval times from 18 to 6 months, encouraging multinational launches. Sub-Saharan Africa remains underserved, with only 22% of patients in South Africa receiving revascularization due to cost and capacity constraints.

Critical Limb Ischemia Treatment Market CAGR (%), Growth Rate by Region

Regulatory Landscape

Regulation for critical limb ischemia (CLI) devices and advanced therapies is increasingly shaped by expedited pathways and higher expectations for long-term safety evidence. In the United States, the FDA has used breakthrough and novel review mechanisms to accelerate limb-salvage technologies, including approval of the LimFlow System (P220025) for no-option chronic limb-threatening ischemia. This reinforces an indication-specific route that leans heavily on amputation-free survival and durable patency endpoints.

In Europe, market access continues to be influenced by MDR implementation and parallel efforts to reduce innovation bottlenecks. The European Commission has been running a targeted evaluation and reform discussion for MDR/IVDR through 2025-2026, while the Medical Device Coordination Group (MDCG) issued 2025 updates to the European Medical Device Nomenclature (EMDN) that add and refine peripheral vascular device categories, affecting conformity assessment alignment and post-market coding. For drugs and clinical development standards, EMA finalized a modernized guideline on peripheral arterial occlusive disease (replacing a 2002 framework), and professional guidance such as the European Society for Vascular Surgery (ESVS) 2026 focused update on paclitaxel-coated technologies continues to shape how coated devices are positioned in EU clinical practice.

Competitive Landscape

The five most prominent companies, Medtronic, Boston Scientific, Abbott Laboratories, Cook Medical, and Terumo, controlled significant revenue in 2025, illustrating moderate concentration. Medtronic generated USD 1.2 billion from CLI balloons and stents in fiscal 2025, but growth slipped to 2.8% amid safety questions. Boston Scientific’s USD 145 million purchase of Bolt Medical in 2024 included the Motus thrombectomy system, which addresses 18% of CLI cases complicated by clot burden. Abbott leveraged the Supera stent’s 89% two-year patency to target below-the-knee disease traditionally owned by Cook Medical’s Zilver PTX. White-space arenas include AI perfusion imaging, where Philips and Siemens are early movers, point-of-care cell processing from Cesca, and deep vein arterialization led solely by LimFlow. Disruptors such as Rexgenero and Micro Medical Solutions are exploiting local cost advantages and novel biologic platforms, eroding incumbent share from below.

Critical Limb Ischemia Treatment Industry Leaders

  1. LimFlow SA

  2. Cardiovascular Systems, Inc

  3. Eli Lilly and Company

  4. Abbott Laboratories

  5. Medtronic

  6. *Disclaimer: Major Players sorted in no particular order
Picture1.png

Critical Limb Ischemia Treatment Market Companies Covered in this Report

  • Abbott Laboratories
  • AngioDynamics
  • B. Braun
  • Biotronik SE & Co.
  • Boston Scientific
  • Cardiovascular Systems
  • Cesca Therapeutics (ThermoGenesis)
  • Cook Group
  • Cynata Therapeutics
  • Eli Lilly and Company
  • LimFlow
  • Medtronic
  • Micro Medical Solutions
  • Koninklijke Philips
  • Pluristem Therapeutics
  • Rexgenero
  • Smiths Group
  • Teva Pharmaceutical Industries
  • Terumo Corp.
  • W. L. Gore & Associates

Read Analysis of Critical Limb Ischemia Treatment Companies

Market Opportunities and Future Outlook

White-space growth is concentrated in below-the-knee (BTK) revascularization and limb-salvage options for no-option CLTI, where repeat interventions and amputation risk keep economic and clinical pressure high. Recent signals include FDA actions supporting novel BTK platforms, such as Abbott's Esprit BTK everolimus-eluting resorbable scaffold approval (April 2024) and Reflow Medical's De Novo clearance for the Spur Peripheral Retrievable Stent System for infrapopliteal disease (May 2025). Alongside deep vein arterialization (DVA) adoption and guideline-driven device scrutiny, these approvals widen the set of reimbursable toolkits for complex infrapopliteal anatomy and support differentiated pricing and site-of-care strategies in hospitals and ambulatory settings.

Regenerative and cell-based approaches remain a key opportunity area because they target failure modes that devices do not fully address, including microvascular dysfunction, poor collateralization, and wound-healing limitations. The pipeline is being reinforced by 2026 research advances in GMP-adaptable hiPSC-derived vascular progenitor cell platforms and engineered biomaterials designed to improve cell retention and angiogenesis, which can shorten translational timelines for companies pursuing scalable cell manufacturing and point-of-care processing models. At the same time, clinical trial activity for PAD and CLTI-adjacent populations, including registry-listed studies and late-stage programs, supports broader physician familiarity with advanced endpoints and can improve patient identification and referral flows into limb-preservation pathways.

Recent Industry Developments in Critical Limb Ischemia Treatment Market

  • February 2026: Eli Lilly and Company reported that protocol modifications for its Phase 3 study (2025-523283-21-00) evaluating orforglipron in patients with peripheral artery disease were accepted by regulatory authorities. The update keeps a large cardiovascular-metabolic player active in PAD, a key upstream driver population for chronic limb-threatening ischemia, and supports continued evidence generation that can shift medical management pathways alongside devices.
  • October 2025: MEDINET signed an option license to commercialize Stempeucel regenerative therapy for chronic limb-threatening ischemia in Japan. The move expands access planning for a cell-based approach in an aging, reimbursement-driven market where coverage for regenerative modalities has been increasing, and it strengthens cross-border commercialization models for advanced therapies.
  • March 2024: Elixir Medical received FDA breakthrough device designation for its DynamX BTK adaptive implant designed for below-the-knee vessels. The designation signals regulatory prioritization for BTK innovation and helps accelerate clinical development and stakeholder engagement for next-generation implants targeting complex infrapopliteal disease.

Table of Contents for Critical Limb Ischemia Treatment Industry Report

1. Introduction

  • 1.1 Study Assumptions & Market Definition
  • 1.2 Scope of the Study

2. Research Methodology

3. Executive Summary

4. Market Landscape

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Rising Diabetes & PAD Prevalence
    • 4.2.2 Growing Adoption of Minimally Invasive Revascularization Devices
    • 4.2.3 Aging Population Intensifying CLI Incidence
    • 4.2.4 FDA Breakthrough Designations Speeding BTK Device & Cell-Therapy Launches
    • 4.2.5 Expansion of Multispecialty Limb-Preservation Centers
    • 4.2.6 AI-Enabled Perfusion Imaging Improving Patient Selection
  • 4.3 Market Restraints
    • 4.3.1 High Cost & Limited Reimbursement in Emerging Economies
    • 4.3.2 Underdiagnosis and Late Presentation
    • 4.3.3 Paclitaxel Device Safety Controversy
    • 4.3.4 Shortage of Trained Vascular Specialists
  • 4.4 Regulatory Landscape
  • 4.5 Technological Outlook
  • 4.6 Porter’s Five Forces Analysis
    • 4.6.1 Threat of New Entrants
    • 4.6.2 Bargaining Power of Buyers
    • 4.6.3 Bargaining Power of Suppliers
    • 4.6.4 Threat of Substitutes
    • 4.6.5 Competitive Rivalry

5. Market Size & Growth Forecasts

  • 5.1 By Treatment Type
    • 5.1.1 Devices
    • 5.1.1.1 Embolic Protection Devices
    • 5.1.1.2 Peripheral Dilatation Systems
    • 5.1.1.3 Balloon Dilators
    • 5.1.1.4 Vascular & Drug-Eluting Stents
    • 5.1.2 Drugs
    • 5.1.2.1 Antiplatelet Agents
    • 5.1.2.2 Antihypertensive Agents
    • 5.1.2.3 Lipid-Lowering Agents
    • 5.1.2.4 Antithrombotic Agents
    • 5.1.3 Regenerative & Cell-Based Therapies
  • 5.2 By End-User
    • 5.2.1 Hospitals
    • 5.2.2 Ambulatory Surgical Centers
    • 5.2.3 Specialty Vascular & Wound-Care Clinics
  • 5.3 By Geography
    • 5.3.1 North America
    • 5.3.1.1 United States
    • 5.3.1.2 Canada
    • 5.3.1.3 Mexico
    • 5.3.2 Europe
    • 5.3.2.1 Germany
    • 5.3.2.2 United Kingdom
    • 5.3.2.3 France
    • 5.3.2.4 Italy
    • 5.3.2.5 Spain
    • 5.3.2.6 Rest of Europe
    • 5.3.3 Asia-Pacific
    • 5.3.3.1 China
    • 5.3.3.2 Japan
    • 5.3.3.3 India
    • 5.3.3.4 Australia
    • 5.3.3.5 South Korea
    • 5.3.3.6 Rest of Asia-Pacific
    • 5.3.4 Middle East & Africa
    • 5.3.4.1 GCC
    • 5.3.4.2 South Africa
    • 5.3.4.3 Rest of Middle East & Africa
    • 5.3.5 South America
    • 5.3.5.1 Brazil
    • 5.3.5.2 Argentina
    • 5.3.5.3 Rest of South America

6. Competitive Landscape

  • 6.1 Market Concentration
  • 6.2 Market Share Analysis
  • 6.3 Company Profiles (includes Global level Overview, Market-level Overview, Core Segments, Financials, Strategic Information, Market Rank/Share, Products & Services, Recent Developments)
    • 6.3.1 Abbott Laboratories
    • 6.3.2 AngioDynamics
    • 6.3.3 B. Braun Melsungen AG
    • 6.3.4 Biotronik SE & Co.
    • 6.3.5 Boston Scientific Corporation
    • 6.3.6 Cardiovascular Systems Inc.
    • 6.3.7 Cesca Therapeutics (ThermoGenesis)
    • 6.3.8 Cook Medical
    • 6.3.9 Cynata Therapeutics
    • 6.3.10 Eli Lilly and Company
    • 6.3.11 LimFlow SA
    • 6.3.12 Medtronic
    • 6.3.13 Micro Medical Solutions
    • 6.3.14 Philips Healthcare
    • 6.3.15 Pluristem Therapeutics
    • 6.3.16 Rexgenero Ltd.
    • 6.3.17 Smith & Nephew
    • 6.3.18 Teva Pharmaceuticals
    • 6.3.19 Terumo Corp.
    • 6.3.20 W. L. Gore & Associates

7. Market Opportunities & Future Outlook

  • 7.1 White-space & Unmet-need Assessment

Critical Limb Ischemia Treatment Market Report Scope and Research Methodology

Market Definition and Coverage

This market covers revenue generated from treatments used to manage critical limb ischemia by restoring or maintaining blood flow and supporting limb salvage, across drugs, devices, and relevant procedures in routine clinical care.

Scope exclusions: Diagnostic imaging platforms and therapies meant only for earlier intermittent claudication are not counted.

Segments Covered in This Report

  • By Treatment Type
    • Devices
      • Embolic Protection Devices
      • Peripheral Dilatation Systems
      • Balloon Dilators
      • Vascular & Drug-Eluting Stents
    • Drugs
      • Antiplatelet Agents
      • Antihypertensive Agents
      • Lipid-Lowering Agents
      • Antithrombotic Agents
    • Regenerative & Cell-Based Therapies
  • By End-User
    • Hospitals
    • Ambulatory Surgical Centers
    • Specialty Vascular & Wound-Care Clinics
  • By Geography
    • North America
      • United States
      • Canada
      • Mexico
    • Europe
      • Germany
      • United Kingdom
      • France
      • Italy
      • Spain
      • Rest of Europe
    • Asia-Pacific
      • China
      • Japan
      • India
      • Australia
      • South Korea
      • Rest of Asia-Pacific
    • Middle East & Africa
      • GCC
      • South Africa
      • Rest of Middle East & Africa
    • South America
      • Brazil
      • Argentina
      • Rest of South America

Data Sources, Market Sizing, and Validation

Desk Research

To build the base structure of the model, we start with public and official sources that help size the patient and procedure pool and explain care pathways. Sources used include items such as the World Health Organization health statistics, Centers for Disease Control and Prevention publications, U.S. FDA device and safety databases, and OECD health data for treatment access and utilization signals. For supporting clinical context, we also review peer-reviewed vascular and cardiology journals and guidance from vascular surgery and cardiovascular associations.

Alongside these, we use company annual reports, regulatory updates, investor presentations, and reputable healthcare press to understand portfolio mix, geographic exposure, and pricing direction. We also reference select paid subscriptions for company financials and intelligence, patent databases, and shipment-level import and export checks when device flow needs clarification. The desk sources listed here are illustrative and not exhaustive, and many other public references are used for cross-checks and clarification during the work.

Primary Interviews and Surveys

Primary work is used to pressure-test the model assumptions around therapy mix, setting shifts, and pricing behavior across the forecast window. We speak with stakeholders across device and drug supply, clinicians, and procurement and reimbursement facing roles, covering major regions so gaps from desk inputs can be closed and final totals can be reconciled to real-world care patterns.

Distribution of primary research fieldwork respondents

Company typeRespondent positionRegion
Top tier: 37% CXOs: 16%APAC: 48%
Mid tier: 44% Functional/Unit leaders: 26%EMEA: 32%
Smaller Players: 19% Managers: 58%Americas: 20%

Market-Sizing & Forecasting

The core model is built using a top-down approach where prevalence and treated-pool logic is converted into spend by linking care pathways to procedure volumes and typical therapy baskets. Because the condition is not managed with one single product, the sizing is anchored on a few practical building blocks such as the CLI patient pool, revascularization procedure counts, amputation and limb-salvage trends, adoption of endovascular versus surgical routes, and setting mix across hospitals and ambulatory centers.

To make sure the totals stay realistic, results are then corroborated with selective bottom-up approximations, including sampled ASP times volume checks for key device and drug categories and limited supplier and channel conversations for mix sanity. Where direct volume signals are weak in a country, we bridge gaps using proxy indicators like diabetes prevalence, peripheral artery disease burden, specialist density, and reimbursement access, and then the assumptions are re-checked through follow-up calls.

For forecasting, we rely on scenario analysis supported by variable-level direction from interviews, and then the trajectory is smoothed against historical demand indicators so sudden jumps are avoided unless a clear trigger exists. Key forward drivers that are explicitly modeled include aging population, diabetes rates, hospital capacity and cath-lab activity, guideline-driven use of revascularization, and price movement as product mix changes over time.

Data Validation & Update Cycle

Outputs are checked using multiple layers so the model does not drift away from observable healthcare signals. We compare derived totals against independent indicators like procedure volumes, treatment rates, and regional spending patterns, and then we run variance checks by geography to spot outliers that are not supported by the underlying inputs.

Before sign-off, the work is reviewed across analysts, and any large deviation triggers a re-check of the patient pool, pricing assumptions, and currency conversion timing. Reports are refreshed annually, and interim adjustments are made when material events occur, such as major regulatory actions, reimbursement changes, or abrupt shifts in procedure activity. Right before delivery, a fresh pass is done so clients receive the most current view available.

Mordor Intelligence's Critical Limb Ischemia Treatment Market Size Compared Against Other Published Estimates

It is common to see different market sizes for critical limb ischemia treatment because each publisher chooses its own timing, scope boundaries, and pricing logic. Differences also show up when procedure intensity is assumed broadly, or when patient pools are not reconciled to how care is actually delivered by region.

In our work, the market value is kept aligned to a consistent annual USD conversion point and an explicit ASP progression by therapy category, and that refresh and validation cadence is one reason Mordor Intelligence lands at a different 2026 value than sources anchored to earlier base years. Another driver is scope handling, where some estimates blend adjacent peripheral artery disease therapies that are not specific to CLI, and others assume faster adoption of premium device mixes without matching it to reimbursement and site-of-care realities.

Benchmark comparison

SourceMarket SizeGaps in Research Methodology
Mordor Intelligence USD 5.47 B (2026)
Global Consultancy A USD 5.09 B (2024)Uses a 2024 base and a broader treatment and device grouping, which can pull in earlier-stage PAD therapies, and it applies a faster growth path that lifts the implied 2026 run-rate.
Industry Publisher B USD 5.12 B (2024)Anchors sizing to a 2024 base with a longer forecast window, and the higher implied near-term growth can come from more aggressive uptake and pricing assumptions that are not always tied back to procedure capacity and reimbursement checks.

The spread in published values mostly comes from base-year choice, how tightly CLI-only therapies are separated from adjacent PAD care, and how price and mix are carried forward. When the patient pool, procedure pathway, and ASP movements are kept transparent and reviewed against external signals, the resulting market size becomes easier to reproduce and explain during decision-making discussions.

Key Questions Answered in the Report

How large is the critical limb ischemia treatment market in 2026?

The market generated USD 5.47 billion in 2026 and is projected to reach USD 7.03 billion by 2031, growing at a 5.15% CAGR.

Which treatment segment is expanding fastest?

Regenerative and cell-based therapies are advancing at a 10.06% CAGR, outpacing both devices and drugs.

Why are ambulatory surgical centers gaining share in CLI procedures?

CMS reimbursement and same-day discharge protocols make ASCs cost-effective, enabling them to perform 28% of U.S. interventions in 2025.

What is driving rapid growth in Asia-Pacific?

China’s approval of locally made drug-eluting devices and India’s expansion of Ayushman Bharat coverage are propelling an 11.53% regional CAGR.

Which companies lead the competitive landscape?

Medtronic, Boston Scientific, Abbott Laboratories, Cook Medical, and Terumo together generate significant revenue, but new entrants in biologics and imaging are challenging their dominance.

Page last updated on: